Global Chronic Kidney Disease Drugs 麻豆原创 Research Report 2025

Publication ID:

PB501251016

Publication Date:

January 3, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Chronic Kidney Disease Drugs was valued at US$ 11390 million in the year 2024 and is projected to reach a revised size of US$ 12880 million by 2031, growing at a CAGR of 1.8% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chronic Kidney Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Kidney Disease Drugs.
The Chronic Kidney Disease Drugs market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Kidney Disease Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Kidney Disease Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Keryx Biopharmaceuticals, Inc
Kissei Pharmaceutical Co., Ltd
AbbVie
GlaxoSmithKline
Sanofi
F. Hoffmann-La Roche Ltd
Pfizer
AstraZeneca
Amgen
Teva Pharmaceutical Industries
Segment by Type
ACE Inhibitors
Calcium Channel Blockers
Beta Blockers
Others
Segment by Application
Hospitals
Specialty Clinics
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Chronic Kidney Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Chronic Kidney Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Chronic Kidney Disease Drugs 麻豆原创 Overview
1.1 Product Definition
1.2 Chronic Kidney Disease Drugs by Type
1.2.1 Global Chronic Kidney Disease Drugs 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 ACE Inhibitors
1.2.3 Calcium Channel Blockers
1.2.4 Beta Blockers
1.2.5 Others
1.3 Chronic Kidney Disease Drugs by Application
1.3.1 Global Chronic Kidney Disease Drugs 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Global Chronic Kidney Disease Drugs 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Chronic Kidney Disease Drugs Revenue 2020-2031
1.4.2 Global Chronic Kidney Disease Drugs Sales 2020-2031
1.4.3 Global Chronic Kidney Disease Drugs 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Chronic Kidney Disease Drugs 麻豆原创 Competition by Manufacturers
2.1 Global Chronic Kidney Disease Drugs Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Chronic Kidney Disease Drugs Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Chronic Kidney Disease Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Chronic Kidney Disease Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Chronic Kidney Disease Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Chronic Kidney Disease Drugs, Product Type & Application
2.7 Global Key Manufacturers of Chronic Kidney Disease Drugs, Date of Enter into This Industry
2.8 Global Chronic Kidney Disease Drugs 麻豆原创 Competitive Situation and Trends
2.8.1 Global Chronic Kidney Disease Drugs 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Chronic Kidney Disease Drugs Players 麻豆原创 Share by Revenue
2.8.3 Global Chronic Kidney Disease Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Chronic Kidney Disease Drugs 麻豆原创 Scenario by Region
3.1 Global Chronic Kidney Disease Drugs 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Chronic Kidney Disease Drugs Sales by Region: 2020-2031
3.2.1 Global Chronic Kidney Disease Drugs Sales by Region: 2020-2025
3.2.2 Global Chronic Kidney Disease Drugs Sales by Region: 2026-2031
3.3 Global Chronic Kidney Disease Drugs Revenue by Region: 2020-2031
3.3.1 Global Chronic Kidney Disease Drugs Revenue by Region: 2020-2025
3.3.2 Global Chronic Kidney Disease Drugs Revenue by Region: 2026-2031
3.4 North America Chronic Kidney Disease Drugs 麻豆原创 Facts & Figures by Country
3.4.1 North America Chronic Kidney Disease Drugs 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Chronic Kidney Disease Drugs Sales by Country (2020-2031)
3.4.3 North America Chronic Kidney Disease Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Chronic Kidney Disease Drugs 麻豆原创 Facts & Figures by Country
3.5.1 Europe Chronic Kidney Disease Drugs 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Chronic Kidney Disease Drugs Sales by Country (2020-2031)
3.5.3 Europe Chronic Kidney Disease Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Chronic Kidney Disease Drugs 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Chronic Kidney Disease Drugs 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Chronic Kidney Disease Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Chronic Kidney Disease Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Chronic Kidney Disease Drugs 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Chronic Kidney Disease Drugs 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Chronic Kidney Disease Drugs Sales by Country (2020-2031)
3.7.3 Latin America Chronic Kidney Disease Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Chronic Kidney Disease Drugs 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Chronic Kidney Disease Drugs 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Chronic Kidney Disease Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Chronic Kidney Disease Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Chronic Kidney Disease Drugs Sales by Type (2020-2031)
4.1.1 Global Chronic Kidney Disease Drugs Sales by Type (2020-2025)
4.1.2 Global Chronic Kidney Disease Drugs Sales by Type (2026-2031)
4.1.3 Global Chronic Kidney Disease Drugs Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Chronic Kidney Disease Drugs Revenue by Type (2020-2031)
4.2.1 Global Chronic Kidney Disease Drugs Revenue by Type (2020-2025)
4.2.2 Global Chronic Kidney Disease Drugs Revenue by Type (2026-2031)
4.2.3 Global Chronic Kidney Disease Drugs Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Chronic Kidney Disease Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Chronic Kidney Disease Drugs Sales by Application (2020-2031)
5.1.1 Global Chronic Kidney Disease Drugs Sales by Application (2020-2025)
5.1.2 Global Chronic Kidney Disease Drugs Sales by Application (2026-2031)
5.1.3 Global Chronic Kidney Disease Drugs Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Chronic Kidney Disease Drugs Revenue by Application (2020-2031)
5.2.1 Global Chronic Kidney Disease Drugs Revenue by Application (2020-2025)
5.2.2 Global Chronic Kidney Disease Drugs Revenue by Application (2026-2031)
5.2.3 Global Chronic Kidney Disease Drugs Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Chronic Kidney Disease Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Keryx Biopharmaceuticals, Inc
6.1.1 Keryx Biopharmaceuticals, Inc Company Information
6.1.2 Keryx Biopharmaceuticals, Inc Description and Business Overview
6.1.3 Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Product Portfolio
6.1.5 Keryx Biopharmaceuticals, Inc Recent Developments/Updates
6.2 Kissei Pharmaceutical Co., Ltd
6.2.1 Kissei Pharmaceutical Co., Ltd Company Information
6.2.2 Kissei Pharmaceutical Co., Ltd Description and Business Overview
6.2.3 Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Product Portfolio
6.2.5 Kissei Pharmaceutical Co., Ltd Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Company Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AbbVie Chronic Kidney Disease Drugs Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Company Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GlaxoSmithKline Chronic Kidney Disease Drugs Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Company Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sanofi Chronic Kidney Disease Drugs Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 F. Hoffmann-La Roche Ltd
6.6.1 F. Hoffmann-La Roche Ltd Company Information
6.6.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.6.3 F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Product Portfolio
6.6.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Chronic Kidney Disease Drugs Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Company Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 AstraZeneca Chronic Kidney Disease Drugs Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Amgen
6.9.1 Amgen Company Information
6.9.2 Amgen Description and Business Overview
6.9.3 Amgen Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Amgen Chronic Kidney Disease Drugs Product Portfolio
6.9.5 Amgen Recent Developments/Updates
6.10 Teva Pharmaceutical Industries
6.10.1 Teva Pharmaceutical Industries Company Information
6.10.2 Teva Pharmaceutical Industries Description and Business Overview
6.10.3 Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Product Portfolio
6.10.5 Teva Pharmaceutical Industries Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Chronic Kidney Disease Drugs Industry Chain Analysis
7.2 Chronic Kidney Disease Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Chronic Kidney Disease Drugs Production Mode & Process Analysis
7.4 Chronic Kidney Disease Drugs Sales and 麻豆原创ing
7.4.1 Chronic Kidney Disease Drugs Sales Channels
7.4.2 Chronic Kidney Disease Drugs Distributors
7.5 Chronic Kidney Disease Drugs Customer Analysis
8 Chronic Kidney Disease Drugs 麻豆原创 Dynamics
8.1 Chronic Kidney Disease Drugs Industry Trends
8.2 Chronic Kidney Disease Drugs 麻豆原创 Drivers
8.3 Chronic Kidney Disease Drugs 麻豆原创 Challenges
8.4 Chronic Kidney Disease Drugs 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Keryx Biopharmaceuticals, Inc
Kissei Pharmaceutical Co., Ltd
AbbVie
GlaxoSmithKline
Sanofi
F. Hoffmann-La Roche Ltd
Pfizer
AstraZeneca
Amgen
Teva Pharmaceutical Industries

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.